Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 120,238

Document Document Title
WO2017008737A1
Disclosed is a natural medicinal composition for treating involutional melancholia and atypical depressive disorder and use thereof. The formulation of the composition consists in mass percentage of 70%-97.5% sea buckthorn fruit oil and ...  
WO2017008205A1
Provide the compound of generic formula I: The compound can be useful as A2A-receptor antagonist. Use the compound for the preparation of a medicament for the treatment and/or prevention of diseases associated with inhibiting the recepto...  
WO2017010520A1
A composition for protecting optic nerve cells, for preventing or treating glaucoma, for suppressing retinal ganglionic cell death, or slowing the progression of vision loss in humans containing at least one selected from the group consi...  
WO2016199170A3
The present invention disclosed relates to Paliperidone palmitate particles, a process to manufacture the same and pharmaceutical compositions thereof. It further relates to the use of such pharmaceutical compositions in the treatment of...  
WO2017011556A1
The disclosure provides novel forms of phosphorylated tau species and applications thereof, as well as methods of diagnosing and/or treating tau-associated neurodegeneration.  
WO2017009275A1
The present invention relates to compounds of formula I wherein R1 is lower alkyl; R2 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; n is 0, 1 or 2; V/U are independently from each other ...  
WO2017009472A1
The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (nota...  
WO/2017/011352A1
Disclosed herein are bone marrow stromal cells. The bone marrow stromal cells may express and/or secrete TGF-βΙ. The bone marrow stromal cells may express CXCR4. Also disclosed herein is a method of treating pain in a subject in need t...  
WO2017010537A1
Provided are a carnosine dipeptidase 1 inhibitor composition, a use for said composition in order to inhibit carnosine dipeptidase 1, and a method for inhibiting carnosine dipeptidase 1. The present invention demonstrates the discovery o...  
WO2017008638A1
Provided is a recombinant P particle formed from a norovirus capsid P protein of a chimeric A beta 1-m peptide (m being an integer between 6 and 15), wherein the recombinant P particles form an ordered and repetitive antigen array. Also ...  
WO2017009312A1
The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse L...  
WO/2017/009711A1
Phospholipid preparations for the improvement of sleep and/or treatment of sleep disorders. Methods of improving sleep and/or treating sleep disorders comprising administering the same.  
WO/2017/009650A1
The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase L1 (UCHL1) and ub...  
WO2017010414A1
The invention addresses the problem of providing a cell construct of at least a predetermined size that can be produced in a short period of time, and a method for producing the cell construct. The invention provides a cell construct inc...  
WO2017009274A1
The present invention relates to compounds of formula (I) wherein R1' is CH3; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1' and R1 may form together a 1,1 -dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethy...  
WO2016160574A3
The application relates to novel compounds and their use in treating and preventing diseases and conditions mediated by modulation of voltage-gated sodium channels. Novel aryl- and heteroaryl- pyrrolidine-2-carboxamide compounds and phar...  
WO/2017/007938A1
Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B rece...  
WO/2017/004966A1
The present invention relates to a new pyrazine derivative, and preparation method and medical application thereof. The pyrazine derivative can remove a free radical, suppress calcium overload, has an effect of protecting cells, and is u...  
WO/2017/007813A1
Aspects of the invention relate to methods for treating ALS comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding superoxide dismutase...  
WO/2017/007960A1
The present disclosure provides compositions, kits, and methods of promoting neural growth and/or neural survival using IL-17c. The compositions, kits, and methods can be used to promote neural growth and/or neural survival in a variety ...  
WO/2017/007825A1
In one aspect, the disclosure provides methods for treating a neurodegenerative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule and a therapeutically effective...  
WO/2017/006932A1
The present invention relates to a composition for treating peripheral nerve injury, which can promote normal regeneration of nerves when the nerves are injured and consequently can prevent the formation of neuroma to prevent the subsequ...  
WO/2017/005136A1
Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGFβ receptor inhibitors, and BET family bromodomain inhibitors ...  
WO/2017/006048A1
The invention relates to compounds of formula I (I) or the salts thereof, and to the use of same in the pharmaceutical, cosmetic or agrofood industry.  
WO/2017/005711A1
The invention relates to bromodomain-protein-inhibiting, in particular BET-protein-inhibiting, and preferably BRD4-inhibiting phosphorous- and sulfur-substituted benzodiazepine derivatives of the general formula (I), in which R1, R2, R3,...  
WO/2017/007755A1
This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a sub...  
WO/2017/007008A1
Provided are novel low-molecular-weight compounds for suppressing the inductive production of MMPs, especially MMP-9, rather than the constitutive production of MMP-2. The present invention pertains to compounds represented by formula (I...  
WO/2017/006953A1
Provided is a compound having TrkA-inhibiting activity, or a pharmaceutically acceptable salt thereof. The present invention pertains to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceu...  
WO/2017/004811A1
Provided in the application are an active peptide for inhibiting an AMPA receptor and a preparation method and the use thereof. The preparation method for the active peptide comprises the following steps: 1) salmon skin is soaked and the...  
WO/2017/006290A1
The present application relates to a modified release composition comprising nicergoline, or its pharmaceutically acceptable salt thereof, at least one rate-controlling polymer and one or more other pharmaceutically acceptable excipients...  
WO/2017/006407A1
A nerve cell death inhibitor, an anti-Alzheimer's disease agent, a brain hypofunction inhibitor and a drug or food having an anti-Alzheimer's disease effect or a brain hypofunction-inhibiting effect, each containing as an active ingredie...  
WO/2017/003466A1
The subject invention concerns materials and methods for conversion of non- neuronal cells into neurons. The subject invention also concerns methods for screening drugs and other compounds for activity in treating Alzheimer's disease usi...  
WO/2017/000276A1
The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (I) and (II) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). ...  
WO/2017/000869A1
The present invention falls within the technical field of medicines. In particular, the present invention relates to a thiazideamide derivative compound, a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition...  
WO/2017/004385A1
A method for detecting circulating levels of beta amyloid peptides in an individual by administration of one or more inhibitors of an extracellular proteolytic pathway in blood and detection of the beta amyloid peptides in the blood or a...  
WO/2017/004405A1
Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated...  
WO/2017/003935A1
TThe present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depr...  
WO/2017/002829A1
[Problem] To prevent abuse of a pharmacologically active ingredient by an abuser by providing a pharmaceutical composition having an abuse-prevention function (abuse by nasal inhalation, abuse by injection, and abuse by extracting a drug...  
WO/2017/000270A1
The present invention relates to a crystal form A and a crystal form B of sertraline citrate, and preparation methods therefor. The crystal form A and the crystal form B of sertraline citrate have good dissolvability, high dissolution an...  
WO/2017/000277A1
The present invention is directed to substituted triazolo bicycliccompounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The prese...  
WO/2017/001568A1
The invention relates to the use of interleukin 4 for preventing and treating amyotrophic lateral sclerosis. In particular, the invention relates to the use of an interleukin 4 polypeptide, a nucleic acid encoding said polypeptide or a c...  
WO/2017/004408A1
Disclosed are new small molecules having a 4-methylpyrrrolo[l,2-a]pyrimidine- 8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the sma...  
WO/2017/004226A1
The present disclosure relates to the use of inositol-stabilized arginine ("ASI") for improving cognition. For example, in some implementations, methods include administering an amount of ASI effective to improve cognition in humans. Som...  
WO/2017/003995A1
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.  
WO/2017/002865A1
Provided is a core-shell structure having high cutaneous permeability. This core-shell structure is provided with a core part containing a hydrophilic drug having a molecular weight of 400 or higher, and a shell part containing a surfact...  
WO/2017/001812A1
This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment o...  
WO/2017/003469A1
The subject invention concerns materials and methods for treating depression, stress disorders, such as PTSD, anxiety disorders, and/or a neurodegenerative disease or condition in a person or animal. In one embodiment, a person or animal...  
WO/2016/208696A1
Disclosed is a fusion protein comprising brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and anti-human transferrin receptor antibody within a specific range, and enables BDNF administered into bl...  
WO/2016/208602A1
[Problem] The purpose of the present invention is to provide a novel pyrazole derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing same and a pharmaceutical use thereof. [Solution] The pr...  
WO/2016/210180A3
Methods are provided herein for treating mania in mood disorders and other neurological diseases or disorders. The methods provided herein comprise administering a VMAT2 inhibitor to a subject in need thereof. A VMAT2 inhibitor useful in...  

Matches 101 - 150 out of 120,238